MARKET

AVEO

Aveo Pharma
AVEO
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-3.7890
11.58
18.00
521,446,905.00
AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist
AVEO Oncology published a post-hoc analysis of long-term progression free survival, overall survival and safety data from the Phase 3 TIVO-3 trial. FOTIVDA (tivozanib) demonstrated a consistent safety profile in patients with advanced renal cell carcinoma.
Barchart · 02/06 07:10

Webull offers Aveo Pharma stock information, including NASDAQ: AVEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVEO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVEO stock methods without spending real money on the virtual paper trading platform.